Cancer Research UK and Cancer Research Technology – the charity’s development and commercialisation arm – have reached a collaboration agreement with immatics Biotechnologies to trial their new treatment vaccine, IMA950, for glioblastoma multiforme (GMB), one of the most common forms of brain cancer*. IMA950 is the fifth treatment to enter Cancer Research UK’s Clinical Development Partnerships (CDP) scheme and the second one to be completed this year… (Source: Health News from Medical News Today)

Further information:

Article source

Related posts:

1. Columbia University Division of Pediatric Oncology Chooses Millennium Biotechnologies’ Resurgex Select(R) for Multi-Site Clinical Trial
2. Biomodels’ Oral Mucositis Expertise Speeds Up FDA Approval for ActoGeniX’s Phase 1b Trial of AGO13 in Cancer Patients
3. The Side-Out Foundation Hopes To Score Big With Its First Funded Breast Cancer Clinical Trial
4. Developing a european grid infrastructure for cancer research: vision, architecture, and services
5. The AACR to host second cancer research conference in Jordan